FY2025 EPS Estimate for ARS Pharmaceuticals Cut by Analyst

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Investment analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of ARS Pharmaceuticals in a note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($1.44) per share for the year, down from their prior forecast of ($1.21). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million.

A number of other research firms also recently weighed in on SPRY. Oppenheimer initiated coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They issued an “outperform” rating and a $40.00 target price for the company. Scotiabank started coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 target price for the company. Finally, William Blair reiterated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $31.00.

ARS Pharmaceuticals Price Performance

SPRY opened at $14.33 on Monday. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -28.10 and a beta of 0.84. ARS Pharmaceuticals has a 1-year low of $7.55 and a 1-year high of $18.51. The business has a 50 day moving average price of $13.43 and a two-hundred day moving average price of $12.87.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 49,600 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.21, for a total transaction of $556,016.00. Following the sale, the director now directly owns 210,346 shares of the company’s stock, valued at $2,357,978.66. The trade was a 19.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Karas sold 10,000 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now directly owns 7,696 shares in the company, valued at $107,744. This trade represents a 56.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 109,602 shares of company stock valued at $1,311,041 in the last three months. 33.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new position in ARS Pharmaceuticals in the fourth quarter worth about $27,000. ANTIPODES PARTNERS Ltd acquired a new position in ARS Pharmaceuticals in the first quarter worth about $37,000. PNC Financial Services Group Inc. raised its stake in shares of ARS Pharmaceuticals by 78,100.0% in the first quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company’s stock valued at $49,000 after acquiring an additional 3,905 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at approximately $73,000. Finally, BNP Paribas Financial Markets bought a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at approximately $75,000. 68.16% of the stock is currently owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.